Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Abivax
Biotech
Abivax aces phase 3 colitis trials as end of cash runway looms
Across two large, global trials, significantly more patients went into colitis remission when given obefazimod compared to placebo.
Darren Incorvaia
Jul 23, 2025 6:30am
Two biotechs go public while Apnimed bides its time
Oct 2, 2023 11:02am
Oncorus C-suite out the door—Chutes & Ladders
Jun 9, 2023 9:30am
Amarin CEO abruptly resigns—Chutes & Ladders
Apr 7, 2023 9:30am
Facing €200M phase 3 bill, Abivax sells stock at knockdown price
Sep 2, 2022 8:41am
Sofinnova invests in Abivax to delay cash crunch
Jul 12, 2019 8:42am
